SecBot SecBot
SECBOTREPLAY Home › Report › PTGX

PTGX · Protagonist Therapeutics reported a significant year-over-year decline…

Protagonist Therapeutics, Inc · 8-K filed Feb 25, 2026 at 16:08 ET

At the news

MIXEDIMPACT 6/10

8-K filed Feb 25, 2026 at 16:08 ET

Protagonist Therapeutics reported a significant year-over-year decline in revenue and a net loss for 2025, driven by the non-recurrence of large milestone payments from 2024. However, the company highlighted major upcoming catalysts including potential FDA approvals for rusfertide and ICOTYDE, a planned opt-out from profit sharing with Takeda, and a strong cash position extending into 2028.

  • License and collaboration revenue dropped to $46.0 million in 2025 from $434.4 million in 2024, primarily due to the absence of a $300 million upfront payment from Takeda and a $165 million milestone from J&J in 2024.
  • The company reported a net loss of $130.1 million for 2025, compared to net income of $275.2 million in 2024.
  • Cash, cash equivalents, and marketable securities were $646 million as of December 31, 2025, providing a cash runway into at least 2028.
  • The company submitted an NDA for rusfertide and expects a U.S. regulatory decision for ICOTYDE in 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access